PTC Therapeutics reports Q3 2026 results, raises full‑year revenue guidance and acquires ST‑920 gene therapy
PTC Therapeutics announced third‑quarter 2026 revenue of $358 million, including $276 million of product sales, and a net loss of $51.7 million. The company lifted its full‑year 2026 revenue outlook to $1.29‑$1.32 billion and product revenue guidance to $960‑$990 million. It also completed the acquisition of the ST‑920 Fabry disease gene therapy for $111 million upfront, with a BLA submission planned for Q4 2026.
Why it matters
The revenue beat and higher guidance suggest stronger cash‑flow prospects, which may support the company’s cash‑breakeven target this year (the company said). The acquisition adds a potential accelerated‑approval product that could generate additional revenue in 2027.
Key facts
- 1Q3 2026 total revenue was $358 million, including $276 million of product revenue. prnewswire.com
- 2Full‑year 2026 total revenue guidance was raised to $1.29‑$1.32 billion, with product revenue guidance raised to $960‑$990 million. prnewswire.com
- 3Net loss for Q3 2026 was $51.7 million. prnewswire.com
- 4PTC acquired the ST‑920 Fabry disease gene therapy for $111.0 million upfront, with up to $100.0 million in contingent milestones. prnewswire.com
- 5BLA submission for ST‑920 is expected to be completed in Q4 2026. prnewswire.com
- 6Sephience revenue in Q3 2026 was $182 million, up over 20% from Q2 2026. sec.gov
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.